Trade Acorda Therapeutics, Inc. - ACOR CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.4506 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026346% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.004124% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 0.01 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Acorda Therapeutics Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 10.3597 |
Open* | 9.7997 |
1-Year Change* | 1546.18% |
Day's Range* | 9.7997 - 10.4697 |
52 wk Range | 8.98-24.20 |
Average Volume (10 days) | 2,500.00 |
Average Volume (3 months) | 157.91K |
Market Cap | 12.17M |
P/E Ratio | -100.00K |
Shares Outstanding | 1.24M |
Revenue | 111.12M |
EPS | -12.83 |
Dividend (Yield %) | N/A |
Beta | 1.39 |
Next Earnings Date | Mar 7, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 4, 2023 | 10.3597 | 0.5900 | 6.04% | 9.7697 | 10.6397 | 9.7697 |
Dec 1, 2023 | 10.1597 | 0.4000 | 4.10% | 9.7597 | 10.1697 | 9.7097 |
Nov 30, 2023 | 9.9597 | 0.2500 | 2.57% | 9.7097 | 10.0597 | 9.7097 |
Nov 29, 2023 | 9.9597 | 0.3000 | 3.11% | 9.6597 | 9.9597 | 9.5997 |
Nov 28, 2023 | 9.9997 | -0.0400 | -0.40% | 10.0397 | 10.4297 | 9.5997 |
Nov 27, 2023 | 9.6597 | 0.1000 | 1.05% | 9.5597 | 9.9597 | 9.5097 |
Nov 24, 2023 | 9.7297 | 0.2200 | 2.31% | 9.5097 | 9.7297 | 9.5097 |
Nov 22, 2023 | 9.5697 | 0.0100 | 0.10% | 9.5597 | 9.5697 | 9.5597 |
Nov 21, 2023 | 9.5997 | 0.0400 | 0.42% | 9.5597 | 9.6597 | 9.5097 |
Nov 20, 2023 | 9.5597 | -0.0400 | -0.42% | 9.5997 | 9.8097 | 9.5097 |
Nov 17, 2023 | 9.6597 | 0.0600 | 0.63% | 9.5997 | 10.0597 | 9.5897 |
Nov 16, 2023 | 9.5897 | 0.0000 | 0.00% | 9.5897 | 10.0497 | 9.5897 |
Nov 15, 2023 | 9.9697 | 0.3800 | 3.96% | 9.5897 | 10.3597 | 9.5897 |
Nov 14, 2023 | 9.8697 | 0.3400 | 3.57% | 9.5297 | 10.8597 | 9.5297 |
Nov 13, 2023 | 9.8497 | 0.3200 | 3.36% | 9.5297 | 9.8597 | 9.5297 |
Nov 10, 2023 | 9.5297 | 0.0700 | 0.74% | 9.4597 | 9.7597 | 9.4597 |
Nov 9, 2023 | 9.5097 | 0.0500 | 0.53% | 9.4597 | 9.9397 | 9.4597 |
Nov 8, 2023 | 9.5797 | -0.2700 | -2.74% | 9.8497 | 9.8997 | 9.4597 |
Nov 7, 2023 | 9.9797 | 0.3500 | 3.63% | 9.6297 | 10.1697 | 9.6297 |
Nov 6, 2023 | 9.6597 | 0.1700 | 1.79% | 9.4897 | 9.6597 | 9.4897 |
Acorda Therapeutics, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Thursday, March 7, 2024 | ||
Time (UTC) 13:30 | Country US
| Event Q4 2023 Acorda Therapeutics Inc Earnings Release Q4 2023 Acorda Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 118.566 | 129.071 | 152.967 | 192.408 | 471.433 |
Revenue | 118.566 | 129.071 | 152.967 | 192.408 | 471.433 |
Cost of Revenue, Total | 30.332 | 40.787 | 33.513 | 34.849 | 99.31 |
Gross Profit | 88.234 | 88.284 | 119.454 | 157.559 | 372.123 |
Total Operating Expense | 126.764 | 208.109 | 231.043 | 448.967 | 432.947 |
Selling/General/Admin. Expenses, Total | 105.956 | 118.999 | 152.576 | 192.846 | 172.254 |
Research & Development | 0.075 | 0.694 | 1.745 | 2.812 | 5.56 |
Other Operating Expenses, Total | -13.521 | 10.865 | -49.581 | -29.664 | 155.823 |
Operating Income | -8.198 | -79.038 | -78.076 | -256.559 | 38.486 |
Interest Income (Expense), Net Non-Operating | -28.299 | -30.03 | -29.758 | -17.702 | -18.079 |
Other, Net | 1.25 | -0.006 | 0.167 | 0.013 | 0.016 |
Net Income Before Taxes | -35.247 | -109.074 | -107.667 | -274.248 | 20.423 |
Net Income After Taxes | -65.916 | -103.954 | -99.594 | -272.966 | 18.882 |
Minority Interest | 0 | ||||
Net Income Before Extra. Items | -65.916 | -103.954 | -99.594 | -272.966 | 18.882 |
Net Income | -65.916 | -103.954 | -99.594 | -272.966 | 33.682 |
Income Available to Common Excl. Extra. Items | -65.916 | -103.954 | -99.594 | -272.966 | 18.882 |
Income Available to Common Incl. Extra. Items | -65.916 | -103.954 | -99.594 | -272.966 | 33.682 |
Diluted Net Income | -65.916 | -103.954 | -99.594 | -272.966 | 33.682 |
Diluted Weighted Average Shares | 0.98535 | 0.53105 | 0.4042 | 0.39593 | 0.39451 |
Diluted EPS Excluding Extraordinary Items | -66.896 | -195.752 | -246.398 | -689.424 | 47.8621 |
Diluted Normalized EPS | -84.6027 | -188.408 | -146.651 | -324.168 | 47.8621 |
Unusual Expense (Income) | -26.842 | 6 | 62.027 | 222.488 | 0 |
Total Extraordinary Items | 14.8 | ||||
Depreciation / Amortization | 30.764 | 30.764 | 30.763 | 25.636 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 29.675 | 22.258 | 31.47 | 33.511 | 31.051 |
Revenue | 29.675 | 22.258 | 31.47 | 33.511 | 31.051 |
Cost of Revenue, Total | 3.065 | 3.234 | 4.56 | 11.005 | 8.8 |
Gross Profit | 26.61 | 19.024 | 26.91 | 22.506 | 22.251 |
Total Operating Expense | 33.307 | 33.734 | 4.061 | 38.5 | 44.966 |
Selling/General/Admin. Expenses, Total | 21.825 | 22.514 | 26.254 | 22.997 | 29.967 |
Research & Development | 0.004 | 0.001 | 0.009 | 0.014 | 0.025 |
Depreciation / Amortization | 7.691 | 7.691 | 7.691 | 7.691 | 7.691 |
Unusual Expense (Income) | -27.142 | 0 | 0.1 | ||
Other Operating Expenses, Total | 0.722 | 0.294 | -7.311 | -3.207 | -1.617 |
Operating Income | -3.632 | -11.476 | 27.409 | -4.989 | -13.915 |
Interest Income (Expense), Net Non-Operating | -7.715 | -7.478 | -5.835 | -7.449 | -7.454 |
Other, Net | 0.001 | 0.092 | 0 | 0 | 1.25 |
Net Income Before Taxes | -11.346 | -18.862 | 21.574 | -12.438 | -20.119 |
Net Income After Taxes | -9.381 | -16.824 | 19.142 | -13.854 | -46.682 |
Net Income Before Extra. Items | -9.381 | -16.824 | 19.142 | -13.854 | -46.682 |
Net Income | -9.381 | -16.824 | 19.142 | -13.854 | -46.682 |
Income Available to Common Excl. Extra. Items | -9.381 | -16.824 | 19.142 | -13.854 | -46.682 |
Income Available to Common Incl. Extra. Items | -9.381 | -16.824 | 19.142 | -13.854 | -46.682 |
Diluted Net Income | -9.381 | -16.824 | 19.142 | -13.854 | -46.682 |
Diluted Weighted Average Shares | 1.242 | 1.2169 | 1.2192 | 1.2145 | 0.83915 |
Diluted EPS Excluding Extraordinary Items | -7.55314 | -13.8253 | 15.7005 | -11.4072 | -55.6301 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -7.55314 | -13.8253 | 1.23007 | -11.4072 | -55.5526 |
Gain (Loss) on Sale of Assets |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 82.115 | 102.157 | 221.335 | 201.113 | 528.107 |
Cash and Short Term Investments | 37.536 | 45.634 | 71.369 | 125.839 | 445.553 |
Cash & Equivalents | 37.536 | 45.634 | 71.369 | 62.085 | 293.564 |
Short Term Investments | 0 | 63.754 | 151.989 | ||
Total Receivables, Net | 13.866 | 17.002 | 20.193 | 22.083 | 23.43 |
Accounts Receivable - Trade, Net | 13.866 | 17.002 | 20.193 | 22.083 | 23.43 |
Total Inventory | 12.752 | 18.548 | 28.677 | 25.221 | 29.014 |
Prepaid Expenses | 4.312 | 6.574 | 14.807 | 11.574 | 19.384 |
Other Current Assets, Total | 13.649 | 14.399 | 86.289 | 16.396 | 10.726 |
Total Assets | 395.595 | 455.47 | 632.68 | 799.718 | 1299.67 |
Property/Plant/Equipment, Total - Net | 7.89 | 11.133 | 25.744 | 165.977 | 60.519 |
Property/Plant/Equipment, Total - Gross | 14.645 | 46.13 | 61.768 | 230.453 | 117.426 |
Accumulated Depreciation, Total | -6.755 | -34.997 | -36.024 | -64.476 | -56.907 |
Goodwill, Net | 0 | 282.059 | |||
Intangibles, Net | 305.087 | 335.98 | 366.981 | 402.329 | 428.57 |
Other Long Term Assets, Total | 0.503 | 6.2 | 18.62 | 30.299 | 0.411 |
Total Current Liabilities | 37.95 | 54.025 | 137.252 | 86.385 | 140.256 |
Accounts Payable | 9.809 | 10.845 | 12.155 | 26.257 | 48.859 |
Accrued Expenses | 24.192 | 35.043 | 43.247 | 43.538 | 70.269 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 68.631 | 0.603 | 0.616 | |
Other Current Liabilities, Total | 3.949 | 8.137 | 13.219 | 15.987 | 20.512 |
Total Liabilities | 301.973 | 304.333 | 394.725 | 488.898 | 687.683 |
Total Long Term Debt | 167.031 | 178.67 | 166.174 | 218.269 | 343.14 |
Long Term Debt | 167.031 | 178.67 | 166.174 | 218.269 | 343.14 |
Deferred Income Tax | 44.202 | 13.93 | 19.116 | 9.581 | 7.483 |
Other Liabilities, Total | 52.79 | 57.708 | 72.183 | 174.663 | 196.804 |
Total Equity | 93.622 | 151.137 | 237.955 | 310.82 | 611.983 |
Common Stock | 0.024 | 0.013 | 0.009 | 0.048 | 0.048 |
Additional Paid-In Capital | 1029.88 | 1023.14 | 1007.79 | 979.388 | 1005.1 |
Retained Earnings (Accumulated Deficit) | -936.273 | -870.357 | -766.403 | -666.809 | -393.843 |
Treasury Stock - Common | -0.638 | -0.638 | -0.638 | -0.638 | -2.133 |
Other Equity, Total | 0.628 | -1.017 | -2.803 | -1.169 | 2.806 |
Total Liabilities & Shareholders’ Equity | 395.595 | 455.47 | 632.68 | 799.718 | 1299.67 |
Total Common Shares Outstanding | 1.21688 | 0.66221 | 0.4735 | 0.39752 | 0.39518 |
Redeemable Preferred Stock | 0 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 73.728 | 64.914 | 68.094 | 82.115 | 71.692 |
Cash and Short Term Investments | 32.468 | 25.27 | 30.255 | 37.536 | 20.696 |
Cash & Equivalents | 32.468 | 25.27 | 30.255 | 37.536 | 20.696 |
Total Receivables, Net | 11.977 | 13.39 | 9.19 | 13.866 | 14.69 |
Accounts Receivable - Trade, Net | 11.977 | 13.39 | 9.19 | 13.866 | 14.69 |
Total Inventory | 17.942 | 14.797 | 13.465 | 12.752 | 15.252 |
Prepaid Expenses | 5.042 | 5.48 | 4.125 | 4.312 | 5.111 |
Other Current Assets, Total | 6.299 | 5.977 | 11.059 | 13.649 | 15.943 |
Total Assets | 366.344 | 364.696 | 374.906 | 395.595 | 393.339 |
Property/Plant/Equipment, Total - Net | 6.706 | 6.928 | 7.412 | 7.89 | 8.366 |
Intangibles, Net | 282.006 | 289.7 | 297.393 | 305.087 | 312.779 |
Other Long Term Assets, Total | 3.904 | 3.154 | 2.007 | 0.503 | 0.502 |
Total Current Liabilities | 46.294 | 30.386 | 34.739 | 37.95 | 42.023 |
Accounts Payable | 12.33 | 3.175 | 2.854 | 9.809 | 11.505 |
Accrued Expenses | 30.922 | 23.389 | 28.573 | 25.225 | 28.159 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | |||||
Other Current Liabilities, Total | 3.042 | 3.822 | 3.312 | 2.916 | 2.359 |
Total Liabilities | 307.387 | 296.828 | 297.946 | 301.973 | 317.573 |
Total Long Term Debt | 181.043 | 176.164 | 171.496 | 167.031 | 187.689 |
Long Term Debt | 181.043 | 176.164 | 171.496 | 167.031 | 187.689 |
Deferred Income Tax | 38.544 | 39.556 | 41.805 | 44.202 | 42.228 |
Other Liabilities, Total | 41.506 | 50.722 | 49.906 | 52.79 | 45.633 |
Total Equity | 58.957 | 67.868 | 76.96 | 93.622 | 75.766 |
Common Stock | 0.001 | 0.001 | 0.024 | 0.024 | 0.024 |
Additional Paid-In Capital | 1030.24 | 1030.1 | 1029.95 | 1029.88 | 1029.7 |
Retained Earnings (Accumulated Deficit) | -971.366 | -962.478 | -953.097 | -936.273 | -955.415 |
Treasury Stock - Common | -0.638 | -0.638 | -0.638 | -0.638 | -0.638 |
Other Equity, Total | 0.717 | 0.88 | 0.719 | 0.628 | 2.09 |
Total Liabilities & Shareholders’ Equity | 366.344 | 364.696 | 374.906 | 395.595 | 393.339 |
Total Common Shares Outstanding | 1.2421 | 1.2421 | 1.21688 | 1.21688 | 1.21663 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -65.916 | -103.954 | -99.594 | -272.966 | 33.682 |
Cash From Operating Activities | -20.924 | -41.348 | -61.006 | -128.167 | 150.793 |
Cash From Operating Activities | 32.809 | 33.953 | 41.298 | 34.573 | 11.479 |
Non-Cash Items | 10.485 | 3.718 | 9.244 | 151.631 | 58.024 |
Cash Taxes Paid | 0.199 | 0.05 | 0.251 | 2.791 | 20.709 |
Cash Interest Paid | 7.157 | 0.006 | 6.67 | 6.056 | 6.064 |
Changes in Working Capital | 1.698 | 24.935 | -11.954 | -41.405 | 47.608 |
Cash From Investing Activities | -0.136 | 73.778 | 59.36 | -0.505 | -176.865 |
Capital Expenditures | -0.136 | -0.191 | -4.39 | -90.426 | -33.915 |
Other Investing Cash Flow Items, Total | 0 | 73.969 | 63.75 | 89.921 | -142.95 |
Cash From Financing Activities | 0 | -69.655 | -1.668 | -60.55 | 12.797 |
Financing Cash Flow Items | 0 | -1.071 | -4.67 | ||
Issuance (Retirement) of Stock, Net | -0.067 | 13.454 | |||
Foreign Exchange Effects | 0.512 | -0.447 | 1.018 | 0.062 | -0.412 |
Net Change in Cash | -20.548 | -37.672 | -2.296 | -189.16 | -13.687 |
Issuance (Retirement) of Debt, Net | 0 | -69.655 | -0.597 | -55.813 | -0.657 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -16.824 | -65.916 | -85.058 | -71.205 | -24.522 |
Cash From Operating Activities | -7.018 | -20.924 | -29.991 | -28.151 | -13.637 |
Cash From Operating Activities | 7.913 | 32.809 | 24.77 | 16.976 | 8.534 |
Non-Cash Items | 1.407 | 10.485 | 26.468 | 25.186 | -1.122 |
Cash Taxes Paid | 0.006 | 0.199 | 0.133 | 0.133 | 0.005 |
Cash Interest Paid | 0 | 7.157 | 0.947 | 0.947 | 0 |
Changes in Working Capital | 0.486 | 1.698 | 3.829 | 0.892 | 3.473 |
Cash From Investing Activities | 0 | -0.136 | -0.259 | -0.109 | -0.039 |
Capital Expenditures | 0 | -0.136 | -0.259 | -0.109 | -0.039 |
Other Investing Cash Flow Items, Total | 0 | ||||
Cash From Financing Activities | 0 | 0 | 0 | 0 | 0 |
Financing Cash Flow Items | 0 | 0 | 0 | ||
Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | 0 | 0 |
Foreign Exchange Effects | 0.097 | 0.512 | -0.79 | -0.468 | -0.092 |
Net Change in Cash | -6.921 | -20.548 | -31.04 | -28.728 | -13.768 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Davidson Kempner Capital Management LP | Hedge Fund | 4.4397 | 55145 | 1 | 2023-06-30 | HIGH |
Renaissance Technologies LLC | Hedge Fund | 3.6681 | 45561 | 1296 | 2023-06-30 | HIGH |
Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 2.7479 | 34131 | -1 | 2023-06-30 | MED |
Cohen (Ron) | Individual Investor | 0.6029 | 7488 | 0 | 2023-04-24 | LOW |
Telemetry Investments, L.L.C. | Hedge Fund | 0.5334 | 6625 | 6625 | 2022-12-31 | HIGH |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.5215 | 6478 | 4 | 2023-06-30 | LOW |
Wells Fargo Securities, LLC | Research Firm | 0.2997 | 3723 | 1 | 2023-06-30 | HIGH |
Deutsche Bank S.p.A. | Investment Advisor | 0.1369 | 1700 | 0 | 2023-06-30 | LOW |
Morgan Stanley & Co. LLC | Research Firm | 0.1018 | 1264 | 793 | 2023-06-30 | MED |
Sabella (Lauren M) | Individual Investor | 0.0432 | 536 | 1 | 2023-04-24 | LOW |
Clem (Kerry M) | Individual Investor | 0.0406 | 504 | 0 | 2023-04-24 | LOW |
RBC Capital Markets Wealth Management | Research Firm | 0.0403 | 500 | 500 | 2023-06-30 | LOW |
Russell Investments Trust Company | Investment Advisor | 0.0242 | 300 | 0 | 2023-06-30 | LOW |
Group One Trading, L.P. | Research Firm | 0.0164 | 204 | -124 | 2023-06-30 | HIGH |
BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.0131 | 163 | 0 | 2023-06-30 | LOW |
Aperio Group, LLC | Investment Advisor | 0.0109 | 135 | 0 | 2023-06-30 | LOW |
Panem (Sandra) | Individual Investor | 0.0019 | 24 | 0 | 2023-04-24 | LOW |
RBC Dominion Securities, Inc. | Investment Advisor | 0.001 | 13 | 0 | 2023-06-30 | LOW |
Morgan Stanley Smith Barney LLC | Investment Advisor | 0.0008 | 10 | 2 | 2023-06-30 | LOW |
Wells Fargo Bank, N.A. | Bank and Trust | 0.0007 | 9 | 1 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Acorda Therapeutics, Inc. Company profile
About Acorda Therapeutics Inc
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. Its ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation is used in the development of variety of inhaled medicines. Its products include Inbrija (levodopa inhalation powder), Ampyra (dalfampridine), Fampyra (fampridine) and Selincro (nalmefene). It markets Inbrija for intermittent treatment of off episodes, also known as off periods, in people with Parkinson's disease treated with carbidopa/levodopa. Ampyra is a drug to improve walking in adults with multiple sclerosis. Its product pipelines includes ARCUS for acute migraine, Cimaglermin alfa for heart failure and rHIgM22 for multiple sclerosis.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Acorda Therapeutics Inc revenues decreased 16% to $129.1M. Net loss increased 4% to $104M. Revenues reflect License revenue segment decrease from $15M to $0K, Ampyra segment decrease of 14% to $84.6M. Higher net loss reflects Change in fair value of derivative liabi decrease of 97% to $1.2M (income), Changes in fair value of acquired contin increase from $30.9M (income) to $2.9M (expense).
Equity composition
Common Stock $.001 Par, 12/12, 80M auth., 39,804,493 issd. Treasury stock 12,420 shs. at $328K Insiders own 0.24%. IPO: 2/06, 5.5M shs. @ $6.00 by Banc of America Securities LLC,Lazard Capital Markets, Piper Jaffray & SG Cowenn & Co. 6/07, 3.6M Common Stock issd thru privateplacement, by Bank of America & Deuschte Bank & 1.2M shs issd upon conversion.
Industry: | Bio Therapeutic Drugs |
Two Blue Hill Plaza
PEARL RIVER
NEW YORK 10965
US
Income Statement
- Annual
- Quarterly
News

December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com